Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.32 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.31 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.30 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12764402 | 0.86 | — | — | |
| SCHEMBL9972840 | 0.75 | CYP1A2 (0.33) | USP2CYP1A2CYP3A4CYP2C19HTT | |
| SCHEMBL12764385 | 0.75 | P2RY10 (0.38) | USP2KDM4EALDH1A1ALOX15CYP1A2 | |
| SCHEMBL12764387 | 0.73 | P2RY10 (0.37) | USP2KDM4EALDH1A1ALOX15CYP1A2 | |
| SCHEMBL12764376 | 0.68 | PLA2G4B (0.35) | USP2KDM4EALDH1A1ALOX15CYP1A2 | |
| SCHEMBL16408436 | 0.67 | USP2 (0.45) | USP2KDM4EALDH1A1ALOX15CYP1A2 | |
| SCHEMBL8767609 | 0.67 | USP2 (0.53) | USP2CYP1A2CYP3A4CYP2C19HTT | |
| SCHEMBL13924256 | 0.66 | USP2 (0.55) | USP2CYP1A2CYP3A4CYP2C19HTT | |
| SCHEMBL9972820 | 0.66 | PLA2G4B (0.38) | USP2CYP1A2CYP3A4CYP2C19HTT | |
| SCHEMBL7769495 | 0.66 | USP2 (0.56) | USP2CYP1A2CYP3A4CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157659-A1 | AFFINITY PEPTIDES AND METHOD FOR PURIFICATION OF RECOMBINANT PROTEINS | SIGMA-ALDRICH CO. (US) | 2012-06-21 | — | — | US | disclosed |
| US-7799561-B2 | Affinity peptides and method for purification of recombinant proteins | SIGMA-ALDRICH, CO. (US) | 2010-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157659-A1 | AFFINITY PEPTIDES AND METHOD FOR PURIFICATION OF RECOMBINANT PROTEINS | RPS27A, AEBP2, MRPL21 | USP2 2142/4885KDM4E 2683/4885ALDH1A1 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.